Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Secures $6.2M in Private Equity

NEW YORK, Feb. 24 (GenomeWeb News) - Epoch Biosciences has secured $6.2 million of equity funding from institutional investors, the company said today.


Epoch, of Bothell, Wash., expects the funding to occur on the next couple of days. The company will sell approximately 2.5 million shares of its common stock at $2.50 per share and will grant investors five-year warrants to purchase additional shares at an exercise price of $3.89 per share.


The company plans to use the financing to expand its sales and marketing infrastructure, and to develop a new product, MGB Eclipse By Design. In addition, Eclipse plans to launch analyte-specific reagents for clinical laboratories later this year.


The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.